Drug Trial Radar · NCT07257510
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
34
Planned (sponsor's estimate)
Start
Aug 1, 2025
Primary completion
Aug 1, 2028
Study completion Aug 1, 2028
Sponsor
- Lead sponsor
- Peking University Third HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 2, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter trial evaluates the efficacy and safety of pomalidomide combined with orelabrutinib and zuberitamab (POZ) in patients with mantle cell lymphoma (MCL). After six cycles of POZ, patients who achieved minimal residual disease (MRD) negativity received maintenance therapy with orelabrutinib plus zuberitamab for up to 18 cycles. Those with MRD positivity were excluded and received alternative treatments. The primary endpoint is the MRD rate after six cycles of POZ. Secondary endpoints include progression-free survival (PFS), overall survival (OS), MRD rate, objective response rate (ORR), and safety.
Conditions
- Mantle Cell Lymphoma (MCL)
- POZ
Interventions
PomalidomideDrug
4mg/day PO once daily, day1-21/cycle
OrelabrutinibDrug
150mg/day PO once daily
ZuberitamabDrug
375 mg/m² IV on day 1/cycle
ZuberitamabDrug
375 mg/m² IV on day 1 of cycle 7, 10, 13, 16, 19 and 22,
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minimum residual disease (MRD) rateTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.